NRX Pharmaceuticals, Inc. 8-K

What Happened NRx Pharmaceuticals, Inc. (NRXP) announced on June 2, 2026 that it intends to conduct an underwritten public offering of its common stock (par value $0.001 per share). The company issued a press release (attached as Exhibit 99.1 to the 8‑K) announcing the planned offering. The filing notes that the 8‑K itself is not an offer to sell or a solicitation to buy securities.

Key Details

• Announcement date: June 2, 2026 (press release attached as Exhibit 99.1).
• Security: Common stock, par value $0.001 per share.
• Offering type: Underwritten public offering (no number of shares, price range, underwriter identity, or use of proceeds disclosed in the 8‑K).
• Formal disclaimers: Filing states there will be no sale in any jurisdiction where the offer would be unlawful and the 8‑K is not an offering document.

Why It Matters A pending underwritten offering is a capital-raising transaction that can affect shareholders. Because the company did not disclose offering size or price, investors should expect potential share dilution and short-term market impact when terms are announced. Monitor future filings (prospectus or registration statement) for concrete terms, use of proceeds, and underwriter details to assess the offering’s effect on valuation and funding for NRX’s operations.